InvestmentJul 29, 2026, 05:16 PM
HCW Biologics Raises $1.6M via Private Placement
AI Summary
HCW Biologics Inc. announced the pricing of a $1.6 million private placement offering. The company issued 618,682 units, each comprising common stock or a pre-funded warrant, and the right to receive a common stock purchase warrant, to accredited investors including key management. The net proceeds are intended for working capital, general corporate purposes, and continuing clinical development activities. The issuance of the common warrants is contingent upon stockholder approval.
Key Highlights
- Raised approximately $1.6 million in gross proceeds through a private placement.
- Issued an aggregate of 618,682 units to accredited investors.
- Each unit consists of common stock or a pre-funded warrant, plus a common warrant right.
- Company's Founder/CEO, Chairman, and SVP of Business Development participated.
- Net proceeds will fund working capital, general corporate purposes, and clinical development.
- Issuance of Common Warrants is subject to stockholder approval.
- Company agreed to file an S-1 registration statement within 15 trading days.
Price Impact
More from HCWB